Novartis Aktie

129,00 EUR +1,50 EUR +1,18 %

12:31:55

STU

149,23 USD -0,59 USD -0,39 %

vorbörslich12:31:10

BTT

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

KGV19,02Div. Rendite2,23%

WKN907122

ISINUS66987V1098

SymbolNVS

Novartis Aktien News

Sortieren:Datum Meistgelesen

04.05.23GlobeNewswireSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

04.05.23Dow JonesPress Release: Novartis: Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

26.04.23GlobeNewswireNovartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

26.04.23Dow JonesPress Release: Novartis Cosentyx(R) gains -2-

26.04.23Dow JonesPress Release: Novartis Cosentyx(R) gains positive CHMP opinion for hidradenitis suppurativa

26.04.23GlobeNewswireNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

26.04.23Dow JonesPress Release: Novartis to present new data -2-

26.04.23GlobeNewswireNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

26.04.23Dow JonesPress Release: Novartis Phase III APPOINT-PNH -3-

26.04.23Dow JonesPress Release: Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to tr...

25.04.23GlobeNewswireNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

25.04.23Dow JonesPress Release: Novartis delivers strong sales -3-

25.04.23Dow JonesPress Release: Novartis delivers strong sales -2-

25.04.23Dow JonesPress Release: Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

20.04.23GlobeNewswireNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

20.04.23Dow JonesPress Release: Novartis presents new five-year -2-

20.04.23Dow JonesPress Release: Novartis presents new five-year data on disability outcomes and safety of Kesimpta(R) (ofatumumab) in people living with relapsing multiple sc...

03.04.23GlobeNewswireSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

03.04.23Dow JonesPress Release: Novartis: Sandoz receives approval by European Commission for Hyrimoz(R) (adalimumab) high-concentration formulation

31.03.23GlobeNewswireNovartis Entresto receives positive CHMP opinion for pediatric heart failure

31.03.23Dow JonesPress Release: Novartis Entresto receives -2-

31.03.23Dow JonesPress Release: Novartis Entresto receives positive CHMP opinion for pediatric heart failure

27.03.23GlobeNewswireNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

27.03.23Dow JonesPress Release: Novartis Kisqali(R) Phase III -2-

27.03.23Dow JonesPress Release: Novartis Kisqali(R) Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad po...

21.03.23GlobeNewswireSandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

21.03.23Dow JonesPress Release: Novartis: Sandoz receives US FDA approval for biosimilar Hyrimoz(R) (adalimumab-adaz) high-concentration formulation

09.03.23Dow JonesPress Release: Novartis: Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand fo...

20.02.23Dow JonesPress Release: Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

06.02.23Dow JonesPress Release: Novartis: Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA

01.02.23Dow JonesPress Release: Novartis continues to grow with -4-

01.02.23Dow JonesPress Release: Novartis continues to grow with -3-

01.02.23Dow JonesPress Release: Novartis continues to grow with further core margin expansion and achieves important innovation milestones

30.01.23Dow JonesPress Release: Novartis: Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar

08.12.22Dow JonesPress Release: Novartis investigational iptacopan -2-

08.12.22Dow JonesPress Release: Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

06.12.22Dow JonesPress Release: Novartis Kisqali(R) prolonged PFS -2-

06.12.22Dow JonesPress Release: Novartis Kisqali(R) prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2- metastatic breast cancer compared to ...

05.12.22Dow JonesPress Release: Novartis PluvictoTM shows -2-

05.12.22Dow JonesPress Release: Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with ...

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.